Approaches to risk stratification in high risk myeloma

Tailored to fit: New approaches in transplant-ineligible NDMM

Advancements in minimal residual disease detection in myeloma

Novel biomarkers in myeloma: CTCs and cfDNA

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Use of bispecifics and CAR T cells in South America

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Guiding transplant decisions in multiple myeloma with MRD

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients

Optimizing oncology: The future of treatment studies